92 related articles for article (PubMed ID: 21338646)
1. Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR.
Zhang B; Gao B; Dong S; Zhang Y; Wu Y
Regul Toxicol Pharmacol; 2011 Jun; 60(1):73-8. PubMed ID: 21338646
[TBL] [Abstract][Full Text] [Related]
2. High-yield expression, purification and characterization of tumor-targeted IFN-alpha2a.
Meng J; Yan Z; Wu J; Li L; Xue X; Li M; Li W; Hao Q; Wan Y; Qin X; Zhang C; You Y; Han W; Zhang Y
Cytotherapy; 2007; 9(1):60-8. PubMed ID: 17354103
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics of a tumour-targeting therapy candidate rh-IFNα2a-NGR with rh-IFNα2a administered intravenously in mice and rats.
Wang XX; Lu L; Song CL; Qian WN; Zhang SY; Zhang YQ; Wu YJ
J Pharm Pharmacol; 2013 Apr; 65(4):574-81. PubMed ID: 23488787
[TBL] [Abstract][Full Text] [Related]
4. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
[TBL] [Abstract][Full Text] [Related]
5. [SOCS1 knockdown sensitize anti-tumor activity of IFN-alpha2a-NGR].
Huang QC; Lei XY; Liu Y; Sui WJ; Li S; Zhang YQ; Yan Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 May; 26(5):412-5. PubMed ID: 20423643
[TBL] [Abstract][Full Text] [Related]
6. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
7. Preclinical safety evaluation of IFNalpha2a-NGR.
Meng J; Yan Z; Wu Y; Gao M; Li W; Gao F; Wang H; Han W; Zhang Y
Regul Toxicol Pharmacol; 2008 Apr; 50(3):294-302. PubMed ID: 18316145
[TBL] [Abstract][Full Text] [Related]
8. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
Jiang W; Jin G; Ma D; Wang F; Fu T; Chen X; Chen X; Jia K; Marikar FM; Hua Z
PLoS One; 2012; 7(5):e37132. PubMed ID: 22590653
[TBL] [Abstract][Full Text] [Related]
9. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of recombinant RGD-IFN-α2a-core fusion protein in vitro.
Wen Z; Jia Q; Kang X; Lou Y; Zou L; Yang J; Gao J; Han L; Li X
Anticancer Drugs; 2017 Jan; 28(1):31-39. PubMed ID: 27759573
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel.
Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q
Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332
[TBL] [Abstract][Full Text] [Related]
12. A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization.
Ma J; Zhang D; Ying X; Zhao Y; He C; Zhu Q; Han S
Curr Cancer Drug Targets; 2015; 15(6):533-41. PubMed ID: 25850444
[TBL] [Abstract][Full Text] [Related]
13. Novel fusion protein NGR-sIL-24 for targetedly suppressing cancer cell growth via apoptosis.
Valiyari S; Salimi M; Bouzari S
Cell Biol Toxicol; 2020 Apr; 36(2):179-193. PubMed ID: 32239369
[TBL] [Abstract][Full Text] [Related]
14. Tissue-factor fusion proteins induce occlusion of tumor vessels.
Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
[TBL] [Abstract][Full Text] [Related]
15. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
16. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.
Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS
Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of acriflavine in lung adenocarcinoma cell line A549.
Lee CJ; Yue CH; Lin YJ; Lin YY; Kao SH; Liu JY; Chen YH
Anticancer Res; 2014 Nov; 34(11):6467-72. PubMed ID: 25368247
[TBL] [Abstract][Full Text] [Related]
20. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy.
Yang Y; Xie X; Yang Y; Zhang H; Mei X
J Pharm Sci; 2015 Apr; 104(4):1328-39. PubMed ID: 25630979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]